Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.
Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
255
daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
University of Illinois at Chicago
Chicago, Illinois, United States
RECRUITINGWeight change (% kg)
Body weight in kg
Time frame: Baseline to month 6
Total and regional body fat composition and distribution
Total and regional body fat composition and distribution will be measured via whole body DEXA scan
Time frame: Baseline, 6 month and 12 month
Intervention adherence
Measured through electronic diet records and 24 hour dietary recalls
Time frame: Monthly, through month 6
Fasting plasma glucose
From fasting venous blood measured by a commercial lab
Time frame: Baseline, month 3, month 6, month 9, month 12
Plasma cytokines TNF-α, IL-6, IL1-β, and IL-10, %
Multiplex ELISA
Time frame: Baseline, month 3, month 6, month 9, month 12
Plasma 8-isoprostane
ELISA
Time frame: Baseline, month 3, month 6, month 9, month 12
Colonic mucosa gene expression profiling
Commercially available targeted transcriptomics platform
Time frame: Baseline, month 6, month 12
Ki-67, proliferation
Healthy colonic mucosa, immunohistochemistry
Time frame: Baseline, month 6, month 12
c-caspase-3, Bax, apoptosis
Healthy colonic mucosa, immunohistochemistry,
Time frame: Baseline, month 6, month 12
CD3, CD163, pIKKa/b, tissue markers of inflammation
Healthy colonic mucosa, immunohistochemistry
Time frame: Baseline, month 6, month 12
Weight maintenance (% kg)
Maintenance of weight loss
Time frame: Month 6 to month 12
Fasting plasma insulin
From fasting venous blood measured at a commercial lab
Time frame: Baseline, month 3, month 6, month 9, month 12
HOMA-IR
calculated from fasting glucose and insulin using a standard formula
Time frame: Baseline, month 3, month 6, month 9, month 12
Gut Microbiome
Shotgun metagenomics
Time frame: Baseline, month 3 and month 6
Fecal Metabolites
Untargeted Metabolomics
Time frame: Baseline, month 3 and month 6
Saliva microbiota
Untargeted Metabolomics
Time frame: Baseline, month 3, month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.